In Memory of Richard Saitz and Allan Cohen |
|
The CTN community recently lost two beloved members of its family, Richard Saitz (New England Consortium Node) and Allan Cohen (Pacific Node).

Allan Cohen, MA, MFT, CTN Pacific Node
From Louise Haynes, MSW, Southern Consortium Node:
Allan Cohen, our beloved former CTP Rep from the Pacific Node, was a wonderful friend -- one of many I have made during my time with the CTN.
One of my first CTN meetings was in NYC where I boarded a bus taking us to a community program and had the good fortune to sit by Allan. He took me under his wing and guided me through my early months with the CTN. Many wonderful CTP Caucus adventures followed. He was a founding member of the Caucus and provided knowledge, wisdom and humor for many years. He will be greatly missed by so many friends and colleagues.
Richard Saitz, MD, MPH, FACP, DFASAM, CTN New England Consortium Node
Richard Saitz passed away January 15 from pancreatic cancer at the age of 58. He had an international reputation in both alcohol and drug addiction research and was involved with the CTN for many years, most recently serving as the co-lead investigator of CTN-0098 (EXHIT ENTRE). His research focused on screening and brief interventions, integrating substance-related and general health care, and improving the quality of care, particularly in general health settings.
Read more about Dr. Saitz's impressive contributions to Boston University and the addiction field in general in this piece from BU School of Medicine.
From Jeffrey Samet, MD, MA, MPH, New England Consortium Node: We will miss his energy, spirit, and wisdom. Fortunately, we have his contributions to our field to appreciate in the years ahead. Read more here.
From Gail D'Onofrio, MD, MS, New England Consortium Node: I had the wonderful opportunity to have a 5-hour dinner with Rich this past October, as ACEP was in Boston. I remember that dinner was a huge event; multiple courses, and all paired with the finest of wines. We were in it for the long haul and the conversations. I will miss you, my friend. You were taken from us way too soon. Read more here.
|
CTN Trial Progress
Randomizations for Active Studies as of the February 13 trial Progress Report.
CTN-0060-A-1 - Enrolled 795
CTN-0079-A-1 - Enrolled 43
CTN-0080 - Enrolled 76
CTN-0097 - Enrolled 289
CTN-0098 - Enrolled 28
CTN-0099 - Enrolled 917
CTN-0099-A-1 - Enrolled 85
CTN-0100
Discontinuation - Enrolled 32
Retention - Enrolled 160
CTN-0101 - Enrolled 116
CTN-0107 - Enrolled 7
CTN-0108 - Enrolled 1
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
Upcoming Events & Webinars
Save the Date: 2022 CTN Annual Steering Committee Meeting
The National Drug Abuse Treatment Clinical Trials Network (CTN) will hold its Annual Steering Committee Meeting virtually on April 26-28, 2022 from 1:00-5:30pm ET. Please save the date!
More information, including how to register, coming soon.
Webinar: Pathways to Recovery from Addiction in Mutual Help Groups
CTN Western States Node and the Northwest and Pacific Southwest ATTCs
February 23, 2022 | 11:00am-12:30pm PT | 1.5 CE/CME available | Register here
In this webinar, Keith Humphreys, PhD (Stanford University) will explore the landscape of mutual help groups and the diverse mutual help groups that are available to patients. The clinical and cost effectiveness of group and 12-step programs will also be reviewed. Lastly, the clinical and policy implications of mutual help groups for promoting recovery from addiction will be discussed. More information here.
Webinar: "I'm Good": Community Reentry as an Opportunity & Challenge for Improving Young People's Behavioral Health
CTN Youth Special Interest Group
March 18, 2022 | 11:00am - 12:00pm ET | Join Zoom Meeting
The objectives of this talk from Dr. Elizabeth Barnert, MD, MPH, MS (UCLA School of Medicine) are to 1) Describe the health needs and service utilization patterns of young people exiting jail; 2) Explore the perspectives of young people exiting jail about their health and social experiences; and 3) Examine barriers and facilitators for young people’s linkages to care during reentry. More information here.
Dr. Liz Barnert is a pediatrician, associate professor, and researcher at UCLA. She provides clinical care at juvenile hall. Her community-partnered, policymaker engaged research examines health services and other systems of support for young people involved with the criminal legal system.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
News from the Nodes
New England Consortium Node
New website
We would like to invite people to visit our NEW Node website! Find it here: https://www.newenglandconsortiumnode.com/
New article in JAMA Network Open
As opioid-associated deaths and emergency department (ED) visits for opioid overdose continue to rise, improving access to effective treatments for opioid use disorder (OUD) such as buprenorphine has become increasingly critical. What do patients with OUD in the ED feel they need?
This piece from Yale Medicine describes a new paper in JAMA Network Open reporting on a study conducted as part of the ED-CONNECT and Project ED Health CTN trials (CTN-0079 and CTN-0069). Patients in the study noted several ways in which they felt ED-based care could be improved, including ways to reduce stigma, provide on-demand OUD treatment, and improve training for ED staff about addiction. Find the JAMA Network Open article here.
Northeast Node
CTN-0116 PharmICO Sites Confirmed
The lead team of CTN-0116: Implementing a Pharmacist-integrated Collaborative Model for Medication Treatment of Opioid Use Disorder (PharmICO), is proud to announce the four sites chosen to participate in the study. The sites are: Harbor Care, Nashua, NH (Northeast Node); Sugar House Clinic, Salt Lake City, UT (Greater Intermountain Node); Truman Health Services, Albuquerque, NM (Southwest Node); Community Health Care, Tacoma, WA (Pacific Northwest Node).
We look forward to working with these clinics and local Node teams to implement a pharmacist-integrated model of care for the treatment of opioid use disorder and further expand our understanding of the feasibility of implementing this collaborative model in a diverse array of settings. |
New York Node
Protocol Updates
CTN-0101
0101’s at 101! The CTN-0101 Lead Team is proud to announce that the study enrolled its 101st patient participant in the Subthreshold Opioid Use Disorder Prevention (STOP) Trial (CTN-0101) in January.
Study sites continue to have success with recruitment, 112 patient participants have been enrolled as of the end of January, and enrollment will continue recruitment through October 2022.
This novel study is testing the efficacy of a collaborative care model for reducing risky opioid use, and potentially preventing opioid use disorder and other opioid-related health problems, in primary care settings. The team-based STOP intervention is working smoothly at all sites, with excellent coordination between the Nurse Care Managers, Telephone Health Coaches, Primary Care Providers/Clinical Champions, and the research staff.
For more information, contact the Project Manager, Rebecca Stone: rebecca.stone@nyulangone.org
CTN-0062Ot
Clinics seeking to implement screening for substance use need evidence-based guidance on approaches that are best suited to their resources, workflows, and patient populations. The New York Node recently completed a multi-phase study to inform the implementation and feasibility of EHR-integrated substance use screening in primary care (CTN-0062Ot, McNeely LI).
After publishing the primary implementation outcomes in JAMA Network Open, the study team worked with the CTN Dissemination Initiative to create an online tool that guides clinical staff and leaders through developing a plan for implementing drug and alcohol screening in primary care.
We are excited to announce that it went live in January 2022 and can be accessed at the following link: https://alcoholdrugscreening.simmersion.com/
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New in the CTN Dissemination Library
Cost of Hepatitis C Care Facilitation for HIV/Hepatitis C Co-Infected People Who Use Drugs. Gutkind S, Starbird LE, Murphy SM, et al. Drug and Alcohol Dependence 2022;232:109265.
"This Could Be My Last Chance": Therapeutic Optimism in a Randomised Controlled Trial for Substance Use Disorders. Jaffe K, Korthuis PT, Richardson L. Sociology of Health & Illness 2021; 43(5):1289-1300.
Association Between Methadone or Buprenorphine Use During Medically Supervised Opioid Withdrawal and Extended-Release Injectable Naltrexone Induction Failure. Shulman M, Choo T, Scodes J, et al. Journal of Substance Abuse Treatment 2021;124:108292.
Evaluating Cannabis Use Risk Reduction as an Alternative Clinical Outcome for Cannabis Use Disorder. Sherma BJ, Sofis MJ, Borodovsky JT, Gray KM, McRae-Clark AL, Budney AJ. Psychology of Addictive Behaviors 2021 (in press).
HIV Clinic-Based Extended Release Naltrexone versus Treatment as Usual for People with HIV and Opioid Use Disorder: A Non-Blinded, Randomised Non-inferiority Trial. Korthuis PT, Cook RR, Lum P, et al. Addiction 2022 (in press).
Changes in Pain During Buprenorphine Maintenance Treatment Among Patients with Opioid Use Disorder and Chronic Pain. Edwards KA, Vowles KE, McHugh RK, Venner KL, Witkiewitz K. Journal of Consulting and Clinical Psychology 2022 (in press).
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
News Releases from NIDA
|
Upcoming Meetings
|
|